| 1 |
35121040 | Human cytochrome P450 3A-mediated two-step oxidation metabolism of dimethomorph: Implications in the mechanism-based enzyme inactivation. | 2022 May 20 |
1 |
| 2 |
35139477 | Synthesis and evaluation of tofacitinib analogs designed to mitigate metabolic activation. | 2022 Apr |
1 |
| 3 |
35512804 | Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of Cytochrome P450 3A. | 2022 May 5 |
2 |
| 4 |
33436520 | Mechanism-Based Inactivation of Cytochrome P450 3A4 by Benzbromarone. | 2021 Apr |
1 |
| 5 |
34326139 | Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4. | 2021 Sep |
1 |
| 6 |
31485694 | Metabolism of carcinogenic alpha-asarone by human cytochrome P450 enzymes. | 2020 Feb |
1 |
| 7 |
31833760 | "Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4": Revisiting the Significance of the Epoxide Intermediate and Glutathione Trapping. | 2020 Feb 17 |
2 |
| 8 |
32469513 | Reply to Letter to Editor from Veeravalli and Dash on "Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4: Revisiting the Significance of the Epoxide Intermediate and Glutathione Trapping". | 2020 Jul 20 |
1 |
| 9 |
30142320 | The critical role of porcine cytochrome P450 3A46 in the bioactivation of aflatoxin B1. | 2018 Oct |
1 |
| 10 |
15572649 | Predictive models of CYP3A4 Heteroactivation: in vitro-in vivo scaling and pharmacophore modeling. | 2005 Mar |
1 |
| 11 |
14672753 | Herbal bioactivation: the good, the bad and the ugly. | 2004 Jan 9 |
1 |
| 12 |
12397847 | Pharmacokinetics of mood stabilizers and new anticonvulsants. | 2002 Winter |
1 |
| 13 |
8261428 | Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. | 1994 Jan 1 |
1 |